References
- Yen SSC. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1975; 12: 177–207
- McKenna TJ. Pathogenesis and treatment of polycystic ovary syndrome. N Engl J Med 1988; 318: 558–62
- Barbieri RL. Polycystic ovarian disease. Ann Rev Med 1991; 42: 199–204
- Barnes R, Rosenfield RL. The polycystic ovary syndrome: pathogenesis and treatment. Ann Intern Med 1989; 110: 386–99
- Sthal NL, Teeslink CR, Greenblatt RB. Ovarian, adrenal and peripheral testosterone levels in the polycystic ovary syndrome. Am J Obstet Gynecol 1973; 117: 194–200
- De Leo V, la Marca A, Talluri B, et al. Hypothalamo–pituitary–adrenal axis and adrenal function before and after ovariectomy in premenopausal women. Eur J Endocrinol 1998; 138: 430–5
- Genazzani AD, Petraglia F, Battaglia C, et al. A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil Steril 1997; 67: 463–8
- Andreiko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J Clin Endocrinol Metab 1986; 63: 854–9
- Lobo RA. Endocrine therapy of hyperandrogenism. Reproductive Endocrine Therapeutics, RL Barbieri, I Schiff. Liss, New York 1988; 101–26
- Carmina E, Janni A, Lobo RA. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism. J Clin Endocrinol Metab 1994; 78: 126–30
- Speroff L, Glass RH, Kase NG. Steroid contraception. Clinical Gynecologic Endocrinology and Infertility, L Speroff, RH Glass, NG Kase. Williams & Wilkins, Baltimore 1989; 461–98
- Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirutism. Fertil Steril 1994; 61: 817–22
- Genazzani AD, Petraglia F, Pianazzi F, et al. The concomitant release of androstenedione with Cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol Endocrinol 1993; 7: 33–41
- Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61: 281–7
- De Leo V, Lanzetta D, D'Antona D, et al. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 99–102
- De Leo V, la Marca A, Lanzetta D, et al. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin relesing factor (CRF). Clin Endocrinol 1998; 49: 85–9
- Hatch R, Rosenfield R, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815–26
- Carr BR, Breslau NA, Givens C, et al. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 1995; 80: 1169–78
- Ciotta L, Cianci A, Giuffrida G, et al. Clinical and hormonal effects of goandotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary syndrome. Fertil Steril 1996; 65: 61–7
- Taskin O, Yalcinoglu Al, Kafkasil A, et al. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary syndrome. Fertil Steril 1996; 65: 1115–8
- Clos V, Esteve A, Jane F, et al. Microsomial effects of cyproterone acetate and flutamide in rat testis. Gen Pharmacol 1988; 19: 393–7
- Brodgen RN, Clissod SP. Flutamide, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 1989; 38: 185–203